New Data from Gilead Continues to Prove Biktarvy's Benefits & More

New data from Gilead Sciences, Inc. regarding HIV research and development was recently presented at the 30th International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2022) in Glasgow, Scotland, as well as virtually from October 23 through 26.

The data supports the company’s current and pipeline innovations in HIV treatment and the latest research from their ongoing cure development program.

The presentation included new "real-world" based data on Biktarvy, evaluating the safety, efficacy and resistance profile of the once-daily single-tablet regimen. The latest findings could aid in the future of coordinated, person-centered HIV care and Biktarvy’s role in long-term treatment.

Other research showed results from two Phase 3 studies evaluating outcomes in adults with HIV who switched to treatment with Biktarvy after 144 weeks of initial treatment with a dolutegravir-based regimen.

The results of a Phase 3 CAPELLA trial evaluating lenacapavir, which was recently approved and marketed in the EU and UK as Sunlenca, was also among the findings presented at the conference.

Dr. Jared Baeten, vice president of the HIV Clinical Development at Gilead, said, “The data presented at HIV Glasgow reflect the latest progress in our research and development programs and underscore Gilead’s commitment to driving transformational innovation in HIV research.”

With a goal of bringing together the broader HIV community to end the epidemic together, he added that Gilead was excited to connect “in person in Scotland at this year’s meeting and sharing these data with the scientific community as we work toward this important goal.”

To learn more about the data presented at HIV Glasgow 2022, click here for a complete list of scientific abstracts from the conference.